Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7379)
All Articles published online
|
Publishing Process of This Article
|
Mar 28, 2014 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chan SL, Yeo W. Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World J Gastroenterol 2014; 20(12): 3135-3145 [PMID: 24696599 DOI: 10.3748/wjg.v20.i12.3135] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i12/3135.htm |
| Number | Citing Articles |
| 1 |
Ying Wang, Xinquan Liu, Guangpu Liu, Hejian Guo, Caiyun Li, Yongchun Zhang, Fang Zhang, Zhongxi Zhao, Huiling Cheng. Novel galactosylated biodegradable nanoparticles for hepatocyte-delivery of oridonin. International Journal of Pharmaceutics 2016; 502(1-2): 47 doi: 10.1016/j.ijpharm.2016.02.025
|
| 2 |
Stephen L. Chan, Alissa M. Wong, Kirsty Lee, Nathalie Wong, Allen K.C. Chan. Personalized therapy for hepatocellular carcinoma: Where are we now?. Cancer Treatment Reviews 2016; 45: 77 doi: 10.1016/j.ctrv.2016.02.008
|
| 3 |
Minjong Lee, Ara Jo, Seulki Lee, Jong Bin Kim, Young Chang, Joon Yeul Nam, Hyeki Cho, Young Youn Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim, Yuan-Soon Ho. 3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. PLOS ONE 2017; 12(3): e0174271 doi: 10.1371/journal.pone.0174271
|
| 4 |
Jieun Bang, Mihyeon Jun, Soyun Lee, Hyuk Moon, Simon Weonsang Ro. Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma. Pharmaceutics 2023; 15(8): 2130 doi: 10.3390/pharmaceutics15082130
|
| 5 |
Stephen L Chan, Anthony WH Chan, Winnie Yeo. Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opinion on Therapeutic Targets 2015; 19(7): 973 doi: 10.1517/14728222.2015.1031109
|
| 6 |
Hyung Joon Yim, Sang Jun Suh, Soon Ho Um. Current management of hepatocellular carcinoma: An Eastern perspective. World Journal of Gastroenterology 2015; 21(13): 3826-3842 doi: 10.3748/wjg.v21.i13.3826
|
| 7 |
Ann‐Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, Wattana Sukeepaisarnjaroen, Tsai‐Shen Yang, Cheng‐Chung Wu, Yee Chao, Stephen L. Chan, Masatoshi Kudo, Masafumi Ikeda, Yoon‐Koo Kang, Hongming Pan, Kazushi Numata, Guohong Han, Binaifer Balsara, Yong Zhang, Ana‐Marie Rodriguez, Yi Zhang, Yongyu Wang, Ronnie T. P. Poon. Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 2016; 64(3): 774 doi: 10.1002/hep.28600
|
| 8 |
Myoung-Eun Han, Ji-Young Kim, Ga Hyun Kim, Si Young Park, Yun Hak Kim, Sae-Ock Oh. SAC3D1: a novel prognostic marker in hepatocellular carcinoma. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-34129-9
|
| 9 |
Zhenglu Wang, Bowen Bi, Hongli Song, Lei Liu, Hong Zheng, Shusen Wang, Zhongyang Shen. Proliferation of human hepatocellular carcinoma cells from surgically resected specimens under conditionally reprogrammed culture. Molecular Medicine Reports 2019; doi: 10.3892/mmr.2019.10160
|
| 10 |
Junying Wang, Daniel J. McGrail, Parnit K. Bhupal, Wen Zhang, Kuan-Yu Lin, Yi-Hsuan Ku, Tao Lin, Hongfu Wu, Kyle C. Tsai, Kaiyi Li, Cheng-Yuan Peng, Milton J. Finegold, Shiaw-Yih Lin, Robert Y.L. Tsai. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress. Molecular Cancer Research 2020; 18(5): 723 doi: 10.1158/1541-7786.MCR-19-0777
|